False negative rate of COVID-19 PCR testing: a discordant testing analysis

COVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR). Performance of many SARS-CoV-2 rtRT-PCR assays is not entirely known due to the lack of a gold standard. We sought to evaluate the false negative rate (FNR) and sensitivi...

Full description

Saved in:
Bibliographic Details
Published inVirology journal Vol. 18; no. 1; p. 13
Main Authors Kanji, Jamil N., Zelyas, Nathan, MacDonald, Clayton, Pabbaraju, Kanti, Khan, Muhammad Naeem, Prasad, Abhaya, Hu, Jia, Diggle, Mathew, Berenger, Byron M., Tipples, Graham
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 09.01.2021
BioMed Central
BMC
Subjects
Adult
Aged
Aged, 80 and over
Alberta
Canada
clinical examination
Coronaviruses
COVID-19
COVID-19 - diagnosis
COVID-19 - virology
COVID-19 infection
COVID-19 Nucleic Acid Testing - statistics & numerical data
Discordant testing
DNA-directed RNA polymerase
Evaluation
False negative rate
False Negative Reactions
False negative results
Female
Genes
Health aspects
Humans
Infections
Male
Medical laboratories
Middle Aged
Molecular Diagnostic Techniques - statistics & numerical data
nucleocapsid
Nucleocapsids
Pandemics
Patients
Polymerase chain reaction
Public health
Real-Time Polymerase Chain Reaction
reverse transcriptase polymerase chain reaction
Ribonucleic acid
RNA
SARS-CoV-2
SARS-CoV-2 - isolation & purification
Sensitivity and Specificity
Severe acute respiratory syndrome coronavirus 2
Short Report
Viral envelope proteins
Viral proteins
virology
viruses
Canada
Alberta Canada
Alberta
COVID-19
Discordant testing
SARS-CoV-2
False negative rate
Online AccessGet full text

Cover

Abstract COVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR). Performance of many SARS-CoV-2 rtRT-PCR assays is not entirely known due to the lack of a gold standard. We sought to evaluate the false negative rate (FNR) and sensitivity of our laboratory-developed SARS-CoV-2 rtRT-PCR targeting the envelope (E) and RNA-dependent RNA-polymerase (RdRp) genes. SARS-CoV-2 rtRT-PCR results at the Public Health Laboratory (Alberta, Canada) from January 21 to April 18, 2020 were reviewed to identify patients with an initial negative rtRT-PCR followed by a positive result on repeat testing within 14 days (defined as discordant results). Negative samples from these discordant specimens were re-tested using three alternate rtRT-PCR assays (targeting the E gene and N1/N2 regions of the nucleocapsid genes) to assess for false negative (FN) results. During the time period specified, 95,919 patients (100,001 samples) were tested for SARS-CoV-2. Of these, 49 patients were found to have discordant results including 49 positive and 52 negative swabs. Repeat testing of 52 negative swabs found five FNs (from five separate patients). Assuming 100% specificity of the diagnostic assay, the FNR and sensitivity in this group of patients with discordant testing was 9.3% (95% CI 1.5-17.0%) and 90.7% (95% CI 82.6-98.9%) respectively. Studies to understand the FNR of routinely used assays are important to confirm adequate clinical performance. In this study, most FN results were due to low amounts of SARS-CoV-2 virus concentrations in patients with multiple specimens collected during different stages of infection. Post-test clinical evaluation of each patient is advised to ensure that rtRT-PCR results are not the only factor in excluding COVID-19.
AbstractList Background COVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR). Performance of many SARS-CoV-2 rtRT-PCR assays is not entirely known due to the lack of a gold standard. We sought to evaluate the false negative rate (FNR) and sensitivity of our laboratory-developed SARS-CoV-2 rtRT-PCR targeting the envelope (E) and RNA-dependent RNA-polymerase (RdRp) genes. Methods SARS-CoV-2 rtRT-PCR results at the Public Health Laboratory (Alberta, Canada) from January 21 to April 18, 2020 were reviewed to identify patients with an initial negative rtRT-PCR followed by a positive result on repeat testing within 14 days (defined as discordant results). Negative samples from these discordant specimens were re-tested using three alternate rtRT-PCR assays (targeting the E gene and N1/N2 regions of the nucleocapsid genes) to assess for false negative (FN) results. Results During the time period specified, 95,919 patients (100,001 samples) were tested for SARS-CoV-2. Of these, 49 patients were found to have discordant results including 49 positive and 52 negative swabs. Repeat testing of 52 negative swabs found five FNs (from five separate patients). Assuming 100% specificity of the diagnostic assay, the FNR and sensitivity in this group of patients with discordant testing was 9.3% (95% CI 1.5-17.0%) and 90.7% (95% CI 82.6-98.9%) respectively. Conclusions Studies to understand the FNR of routinely used assays are important to confirm adequate clinical performance. In this study, most FN results were due to low amounts of SARS-CoV-2 virus concentrations in patients with multiple specimens collected during different stages of infection. Post-test clinical evaluation of each patient is advised to ensure that rtRT-PCR results are not the only factor in excluding COVID-19. Keywords: SARS-CoV-2, COVID-19, Discordant testing, False negative rate
COVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR). Performance of many SARS-CoV-2 rtRT-PCR assays is not entirely known due to the lack of a gold standard. We sought to evaluate the false negative rate (FNR) and sensitivity of our laboratory-developed SARS-CoV-2 rtRT-PCR targeting the envelope (E) and RNA-dependent RNA-polymerase (RdRp) genes. SARS-CoV-2 rtRT-PCR results at the Public Health Laboratory (Alberta, Canada) from January 21 to April 18, 2020 were reviewed to identify patients with an initial negative rtRT-PCR followed by a positive result on repeat testing within 14 days (defined as discordant results). Negative samples from these discordant specimens were re-tested using three alternate rtRT-PCR assays (targeting the E gene and N1/N2 regions of the nucleocapsid genes) to assess for false negative (FN) results. During the time period specified, 95,919 patients (100,001 samples) were tested for SARS-CoV-2. Of these, 49 patients were found to have discordant results including 49 positive and 52 negative swabs. Repeat testing of 52 negative swabs found five FNs (from five separate patients). Assuming 100% specificity of the diagnostic assay, the FNR and sensitivity in this group of patients with discordant testing was 9.3% (95% CI 1.5-17.0%) and 90.7% (95% CI 82.6-98.9%) respectively. Studies to understand the FNR of routinely used assays are important to confirm adequate clinical performance. In this study, most FN results were due to low amounts of SARS-CoV-2 virus concentrations in patients with multiple specimens collected during different stages of infection. Post-test clinical evaluation of each patient is advised to ensure that rtRT-PCR results are not the only factor in excluding COVID-19.
COVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR). Performance of many SARS-CoV-2 rtRT-PCR assays is not entirely known due to the lack of a gold standard. We sought to evaluate the false negative rate (FNR) and sensitivity of our laboratory-developed SARS-CoV-2 rtRT-PCR targeting the envelope (E) and RNA-dependent RNA-polymerase (RdRp) genes.BACKGROUNDCOVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR). Performance of many SARS-CoV-2 rtRT-PCR assays is not entirely known due to the lack of a gold standard. We sought to evaluate the false negative rate (FNR) and sensitivity of our laboratory-developed SARS-CoV-2 rtRT-PCR targeting the envelope (E) and RNA-dependent RNA-polymerase (RdRp) genes.SARS-CoV-2 rtRT-PCR results at the Public Health Laboratory (Alberta, Canada) from January 21 to April 18, 2020 were reviewed to identify patients with an initial negative rtRT-PCR followed by a positive result on repeat testing within 14 days (defined as discordant results). Negative samples from these discordant specimens were re-tested using three alternate rtRT-PCR assays (targeting the E gene and N1/N2 regions of the nucleocapsid genes) to assess for false negative (FN) results.METHODSSARS-CoV-2 rtRT-PCR results at the Public Health Laboratory (Alberta, Canada) from January 21 to April 18, 2020 were reviewed to identify patients with an initial negative rtRT-PCR followed by a positive result on repeat testing within 14 days (defined as discordant results). Negative samples from these discordant specimens were re-tested using three alternate rtRT-PCR assays (targeting the E gene and N1/N2 regions of the nucleocapsid genes) to assess for false negative (FN) results.During the time period specified, 95,919 patients (100,001 samples) were tested for SARS-CoV-2. Of these, 49 patients were found to have discordant results including 49 positive and 52 negative swabs. Repeat testing of 52 negative swabs found five FNs (from five separate patients). Assuming 100% specificity of the diagnostic assay, the FNR and sensitivity in this group of patients with discordant testing was 9.3% (95% CI 1.5-17.0%) and 90.7% (95% CI 82.6-98.9%) respectively.RESULTSDuring the time period specified, 95,919 patients (100,001 samples) were tested for SARS-CoV-2. Of these, 49 patients were found to have discordant results including 49 positive and 52 negative swabs. Repeat testing of 52 negative swabs found five FNs (from five separate patients). Assuming 100% specificity of the diagnostic assay, the FNR and sensitivity in this group of patients with discordant testing was 9.3% (95% CI 1.5-17.0%) and 90.7% (95% CI 82.6-98.9%) respectively.Studies to understand the FNR of routinely used assays are important to confirm adequate clinical performance. In this study, most FN results were due to low amounts of SARS-CoV-2 virus concentrations in patients with multiple specimens collected during different stages of infection. Post-test clinical evaluation of each patient is advised to ensure that rtRT-PCR results are not the only factor in excluding COVID-19.CONCLUSIONSStudies to understand the FNR of routinely used assays are important to confirm adequate clinical performance. In this study, most FN results were due to low amounts of SARS-CoV-2 virus concentrations in patients with multiple specimens collected during different stages of infection. Post-test clinical evaluation of each patient is advised to ensure that rtRT-PCR results are not the only factor in excluding COVID-19.
BACKGROUND: COVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR). Performance of many SARS-CoV-2 rtRT-PCR assays is not entirely known due to the lack of a gold standard. We sought to evaluate the false negative rate (FNR) and sensitivity of our laboratory-developed SARS-CoV-2 rtRT-PCR targeting the envelope (E) and RNA-dependent RNA-polymerase (RdRp) genes. METHODS: SARS-CoV-2 rtRT-PCR results at the Public Health Laboratory (Alberta, Canada) from January 21 to April 18, 2020 were reviewed to identify patients with an initial negative rtRT-PCR followed by a positive result on repeat testing within 14 days (defined as discordant results). Negative samples from these discordant specimens were re-tested using three alternate rtRT-PCR assays (targeting the E gene and N1/N2 regions of the nucleocapsid genes) to assess for false negative (FN) results. RESULTS: During the time period specified, 95,919 patients (100,001 samples) were tested for SARS-CoV-2. Of these, 49 patients were found to have discordant results including 49 positive and 52 negative swabs. Repeat testing of 52 negative swabs found five FNs (from five separate patients). Assuming 100% specificity of the diagnostic assay, the FNR and sensitivity in this group of patients with discordant testing was 9.3% (95% CI 1.5–17.0%) and 90.7% (95% CI 82.6–98.9%) respectively. CONCLUSIONS: Studies to understand the FNR of routinely used assays are important to confirm adequate clinical performance. In this study, most FN results were due to low amounts of SARS-CoV-2 virus concentrations in patients with multiple specimens collected during different stages of infection. Post-test clinical evaluation of each patient is advised to ensure that rtRT-PCR results are not the only factor in excluding COVID-19.
COVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR). Performance of many SARS-CoV-2 rtRT-PCR assays is not entirely known due to the lack of a gold standard. We sought to evaluate the false negative rate (FNR) and sensitivity of our laboratory-developed SARS-CoV-2 rtRT-PCR targeting the envelope (E) and RNA-dependent RNA-polymerase (RdRp) genes. SARS-CoV-2 rtRT-PCR results at the Public Health Laboratory (Alberta, Canada) from January 21 to April 18, 2020 were reviewed to identify patients with an initial negative rtRT-PCR followed by a positive result on repeat testing within 14 days (defined as discordant results). Negative samples from these discordant specimens were re-tested using three alternate rtRT-PCR assays (targeting the E gene and N1/N2 regions of the nucleocapsid genes) to assess for false negative (FN) results. During the time period specified, 95,919 patients (100,001 samples) were tested for SARS-CoV-2. Of these, 49 patients were found to have discordant results including 49 positive and 52 negative swabs. Repeat testing of 52 negative swabs found five FNs (from five separate patients). Assuming 100% specificity of the diagnostic assay, the FNR and sensitivity in this group of patients with discordant testing was 9.3% (95% CI 1.5-17.0%) and 90.7% (95% CI 82.6-98.9%) respectively. Studies to understand the FNR of routinely used assays are important to confirm adequate clinical performance. In this study, most FN results were due to low amounts of SARS-CoV-2 virus concentrations in patients with multiple specimens collected during different stages of infection. Post-test clinical evaluation of each patient is advised to ensure that rtRT-PCR results are not the only factor in excluding COVID-19.
Abstract Background COVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR). Performance of many SARS-CoV-2 rtRT-PCR assays is not entirely known due to the lack of a gold standard. We sought to evaluate the false negative rate (FNR) and sensitivity of our laboratory-developed SARS-CoV-2 rtRT-PCR targeting the envelope (E) and RNA-dependent RNA-polymerase (RdRp) genes. Methods SARS-CoV-2 rtRT-PCR results at the Public Health Laboratory (Alberta, Canada) from January 21 to April 18, 2020 were reviewed to identify patients with an initial negative rtRT-PCR followed by a positive result on repeat testing within 14 days (defined as discordant results). Negative samples from these discordant specimens were re-tested using three alternate rtRT-PCR assays (targeting the E gene and N1/N2 regions of the nucleocapsid genes) to assess for false negative (FN) results. Results During the time period specified, 95,919 patients (100,001 samples) were tested for SARS-CoV-2. Of these, 49 patients were found to have discordant results including 49 positive and 52 negative swabs. Repeat testing of 52 negative swabs found five FNs (from five separate patients). Assuming 100% specificity of the diagnostic assay, the FNR and sensitivity in this group of patients with discordant testing was 9.3% (95% CI 1.5–17.0%) and 90.7% (95% CI 82.6–98.9%) respectively. Conclusions Studies to understand the FNR of routinely used assays are important to confirm adequate clinical performance. In this study, most FN results were due to low amounts of SARS-CoV-2 virus concentrations in patients with multiple specimens collected during different stages of infection. Post-test clinical evaluation of each patient is advised to ensure that rtRT-PCR results are not the only factor in excluding COVID-19.
ArticleNumber 13
Audience Academic
Author Khan, Muhammad Naeem
Pabbaraju, Kanti
Diggle, Mathew
Hu, Jia
Prasad, Abhaya
Kanji, Jamil N.
Zelyas, Nathan
Berenger, Byron M.
Tipples, Graham
MacDonald, Clayton
Author_xml – sequence: 1
  givenname: Jamil N.
  orcidid: 0000-0002-1043-6807
  surname: Kanji
  fullname: Kanji, Jamil N.
– sequence: 2
  givenname: Nathan
  surname: Zelyas
  fullname: Zelyas, Nathan
– sequence: 3
  givenname: Clayton
  surname: MacDonald
  fullname: MacDonald, Clayton
– sequence: 4
  givenname: Kanti
  surname: Pabbaraju
  fullname: Pabbaraju, Kanti
– sequence: 5
  givenname: Muhammad Naeem
  surname: Khan
  fullname: Khan, Muhammad Naeem
– sequence: 6
  givenname: Abhaya
  surname: Prasad
  fullname: Prasad, Abhaya
– sequence: 7
  givenname: Jia
  surname: Hu
  fullname: Hu, Jia
– sequence: 8
  givenname: Mathew
  surname: Diggle
  fullname: Diggle, Mathew
– sequence: 9
  givenname: Byron M.
  surname: Berenger
  fullname: Berenger, Byron M.
– sequence: 10
  givenname: Graham
  surname: Tipples
  fullname: Tipples, Graham
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33422083$$D View this record in MEDLINE/PubMed
BookMark eNqFkktv1DAUhSNURB_wB1igSGzoIuX6EcdmgVQNFAZVKioPsbOc5CZ4lImL7anaf48z05ZOhUBe2Lr-7pHv8dnPdkY3YpY9J3BEiBSvA6FKlgVQUgDhUhXwKNsjFWcFp_THzr3zbrYfwgKAUVGpJ9kuY6kKku1ln07MEDAfsTfRXmLuTcTcdfns7Pv8XUFU_nl2nkcM0Y79m9zkrQ2N860Z4201N6MZroMNT7PH3ST27GY_yL6dvP86-1icnn2Yz45Pi0YwiIXCGjip2w45L9E0lCuZnqLAICWMAaCURqECVtUsTaBYx4wiSGqquo7U7CCbb3RbZxb6wtul8dfaGavXBed7bXy0zYC65mBKxauKouAoRN3StgNJGWlLAtWk9XajdbGql9g2OEZvhi3R7ZvR_tS9u9RVpbggKgm8uhHw7tcqOaKXySEcBjOiWwVNy_QHvKSM_h_llZAloyUk9OUDdOFWPvm8pqRkTAD7Q_UmzWrHzqUnNpOoPhYlCCCCTdTRX6i0WlzaJiWqs6m-1XC41ZCYiFexN6sQ9PzL-Tb74r5_d8bdBiwBdAM03oXgsbtDCOgpxXqTYp1SrNcp1tP48kFTY2PKp5v-wA7_av0NtNXwQg
CitedBy_id crossref_primary_10_15446_dyna_v90n227_107276
crossref_primary_10_1080_1354750X_2021_2016973
crossref_primary_10_3390_bios13050553
crossref_primary_10_17827_aktd_1226153
crossref_primary_10_58854_jicm_1206881
crossref_primary_10_1016_j_tmaid_2022_102334
crossref_primary_10_1055_a_1779_9230
crossref_primary_10_3390_jimaging8090237
crossref_primary_10_36659_dae_2023_057
crossref_primary_10_37871_jbres1334
crossref_primary_10_3389_fmicb_2022_854209
crossref_primary_10_3390_biochem1030018
crossref_primary_10_1016_j_snb_2022_131764
crossref_primary_10_4274_nkmj_galenos_2022_37232
crossref_primary_10_1038_s41598_022_07756_6
crossref_primary_10_29328_journal_ijcv_1001056
crossref_primary_10_3390_jcm10081586
crossref_primary_10_1016_j_aca_2022_340036
crossref_primary_10_1111_eci_13706
crossref_primary_10_1038_s41598_021_87688_9
crossref_primary_10_9778_cmajo_20210064
crossref_primary_10_1002_jmv_27932
crossref_primary_10_1159_000538312
crossref_primary_10_1021_acs_analchem_2c01325
crossref_primary_10_2478_crdj_2021_0012
crossref_primary_10_1109_TIM_2023_3267355
crossref_primary_10_1007_s00216_022_03918_7
crossref_primary_10_1109_MC_2023_3235880
crossref_primary_10_3390_diagnostics12040909
crossref_primary_10_3389_fmicb_2022_1074289
crossref_primary_10_7759_cureus_19341
crossref_primary_10_1016_j_rinp_2021_104529
crossref_primary_10_1007_s11739_021_02758_0
crossref_primary_10_1021_acsomega_4c00735
crossref_primary_10_3389_fpubh_2024_1322797
crossref_primary_10_1016_j_chaos_2024_115869
crossref_primary_10_1016_j_puhe_2021_09_010
crossref_primary_10_1088_1752_7163_ac59c7
crossref_primary_10_1093_cid_ciab345
crossref_primary_10_18678_dtfd_1021421
crossref_primary_10_1016_j_asjsur_2023_05_002
crossref_primary_10_1097_CJI_0000000000000440
crossref_primary_10_2298_SARH230201074S
crossref_primary_10_1002_ccr3_8162
crossref_primary_10_1016_j_medj_2022_01_009
crossref_primary_10_3390_ani11123506
crossref_primary_10_1016_j_ijregi_2022_11_013
crossref_primary_10_33667_2078_5631_2022_33_40_46
crossref_primary_10_1155_2023_9224815
crossref_primary_10_1155_2022_6354579
crossref_primary_10_1016_j_jobb_2021_10_001
crossref_primary_10_3390_diagnostics12030687
crossref_primary_10_1002_ccr3_5579
crossref_primary_10_3390_app12094694
crossref_primary_10_3390_v13050730
crossref_primary_10_1007_s00210_023_02417_5
crossref_primary_10_1097_SLE_0000000000000971
crossref_primary_10_3390_diseases11010020
crossref_primary_10_1007_s11227_023_05156_9
crossref_primary_10_3390_ai2020016
crossref_primary_10_1155_2022_9245248
crossref_primary_10_1080_21681163_2023_2183807
crossref_primary_10_3390_genes13122387
crossref_primary_10_3390_diagnostics13193057
crossref_primary_10_1007_s13665_022_00285_7
crossref_primary_10_2139_ssrn_4284685
crossref_primary_10_5664_jcsm_9898
crossref_primary_10_1007_s00521_023_09154_z
crossref_primary_10_1080_23744235_2022_2080250
crossref_primary_10_1016_j_ejro_2022_100456
crossref_primary_10_3389_fmed_2022_868954
crossref_primary_10_1007_s42399_021_01059_z
crossref_primary_10_1080_01621459_2024_2313790
crossref_primary_10_1016_j_jeconom_2024_105842
crossref_primary_10_4028_p_2gGH9B
crossref_primary_10_7197_cmj_1164858
crossref_primary_10_1016_j_cca_2023_117759
crossref_primary_10_3343_alm_2023_43_4_392
crossref_primary_10_1001_jamanetworkopen_2022_36288
crossref_primary_10_1016_j_clinthera_2021_04_016
crossref_primary_10_1007_s10278_023_00941_7
crossref_primary_10_1186_s43055_023_01099_6
crossref_primary_10_1016_j_applanim_2022_105825
crossref_primary_10_1016_j_trac_2022_116759
crossref_primary_10_1016_j_aca_2025_343872
crossref_primary_10_1016_j_diagmicrobio_2024_116430
crossref_primary_10_1016_j_idcr_2022_e01496
crossref_primary_10_1002_jmv_28416
crossref_primary_10_1039_D1AY00947H
crossref_primary_10_1016_j_sintl_2021_100119
crossref_primary_10_1016_j_jiac_2022_04_002
crossref_primary_10_12991_jrespharm_1626457
crossref_primary_10_1002_jcla_25149
crossref_primary_10_1080_14737159_2022_2037425
crossref_primary_10_1016_j_bios_2025_117145
crossref_primary_10_1017_S0950268822001546
crossref_primary_10_1038_s41598_024_51317_y
crossref_primary_10_1002_smll_202206349
crossref_primary_10_1016_j_jmii_2021_09_005
crossref_primary_10_35825_2587_5728_2022_6_1_56_65
crossref_primary_10_3390_pathogens11121442
crossref_primary_10_1007_s00508_022_02028_9
crossref_primary_10_1128_Spectrum_00291_21
crossref_primary_10_3390_bios11120510
crossref_primary_10_1017_cts_2023_540
crossref_primary_10_1038_s41598_021_98114_5
crossref_primary_10_1007_s40200_022_01002_6
crossref_primary_10_14712_23362936_2023_22
crossref_primary_10_1088_1361_6560_ac34b2
crossref_primary_10_1371_journal_pone_0262631
crossref_primary_10_3390_info14070370
crossref_primary_10_1007_s10900_021_00988_z
crossref_primary_10_2139_ssrn_4019593
crossref_primary_10_18621_eurj_1185361
crossref_primary_10_1055_s_0041_1735148
crossref_primary_10_1001_jamanetworkopen_2023_0982
crossref_primary_10_5812_jjm_116533
crossref_primary_10_1128_spectrum_01477_22
crossref_primary_10_1177_00033197231152941
crossref_primary_10_1016_j_scitotenv_2022_155410
crossref_primary_10_1016_j_microc_2022_107585
crossref_primary_10_1016_j_bios_2022_114406
crossref_primary_10_3390_diagnostics12092133
crossref_primary_10_1016_j_wneu_2022_07_137
crossref_primary_10_1155_2022_4510900
crossref_primary_10_1016_j_jmoldx_2021_10_010
crossref_primary_10_3390_jpm11101015
crossref_primary_10_3389_fbioe_2022_1042926
crossref_primary_10_1212_CPJ_0000000000001148
crossref_primary_10_3390_bios14010006
crossref_primary_10_1002_lary_30034
crossref_primary_10_1016_j_xcrm_2022_100580
crossref_primary_10_1038_s41598_022_18735_2
crossref_primary_10_1021_acssensors_1c02450
crossref_primary_10_1007_s00216_021_03831_5
crossref_primary_10_1016_j_transproceed_2024_11_008
crossref_primary_10_1128_msystems_00671_22
crossref_primary_10_1007_s12553_023_00734_6
crossref_primary_10_61186_rbmb_11_2_358
crossref_primary_10_1007_s13748_023_00312_x
crossref_primary_10_1016_j_cyto_2024_156756
Cites_doi 10.1093/clinchem/hvaa091
10.1017/ice.2020.224
10.1148/radiol.2020200642
10.1128/JCM.01110-20
10.1101/2020.02.11.20021493
10.3138/jammi-2020-0026
10.1016/j.mayocp.2020.04.004
10.1101/2020.04.16.20066787
10.1038/s41591-020-0869-5
10.1016/j.jcv.2020.104433
10.1111/irv.12309
10.7326/M20-1495
10.1093/ofid/ofaa559
10.7883/yoken.JJID.2020.165
10.1093/infdis/jiaa370
10.1128/JCM.00753-20
10.1016/j.jare.2020.08.002
10.1128/JCM.00995-20
10.1093/cid/ciaa848
10.3138/jammi-2020-0012
10.2196/19054
10.1093/cid/ciaa722
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7U9
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
7S9
L.6
5PM
DOA
DOI 10.1186/s12985-021-01489-0
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central (New)
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList

MEDLINE - Academic
AGRICOLA
MEDLINE
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
Public Health
EISSN 1743-422X
EndPage 13
ExternalDocumentID oai_doaj_org_article_b40a594772e64e66bd2df08231d5107b
PMC7794619
A650601633
33422083
10_1186_s12985_021_01489_0
Genre Journal Article
Report
GeographicLocations Canada
Alberta Canada
Alberta
GeographicLocations_xml – name: Canada
– name: Alberta Canada
– name: Alberta
GroupedDBID ---
0R~
123
29Q
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAHBH
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IGS
IHR
INH
INR
ISR
ITC
KQ8
LGEZI
LOTEE
M1P
M48
M~E
NADUK
NXXTH
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7U9
7XB
8FK
AZQEC
COVID
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
7S9
L.6
5PM
PUEGO
ID FETCH-LOGICAL-c630t-9eb041bdfe445eac249808390ae213300e88a9e9037b317493f3a91e1b29ff1b3
IEDL.DBID M48
ISSN 1743-422X
IngestDate Wed Aug 27 01:31:43 EDT 2025
Thu Aug 21 13:52:32 EDT 2025
Tue Aug 05 10:04:39 EDT 2025
Fri Jul 11 09:38:15 EDT 2025
Fri Jul 25 07:37:52 EDT 2025
Tue Jun 17 20:43:44 EDT 2025
Tue Jun 10 20:24:08 EDT 2025
Fri Jun 27 04:03:35 EDT 2025
Thu Apr 03 07:04:00 EDT 2025
Tue Jul 01 01:44:46 EDT 2025
Thu Apr 24 23:07:04 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords COVID-19
Discordant testing
SARS-CoV-2
False negative rate
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c630t-9eb041bdfe445eac249808390ae213300e88a9e9037b317493f3a91e1b29ff1b3
Notes SourceType-Scholarly Journals-1
content type line 14
ObjectType-Report-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-1043-6807
OpenAccessLink https://www.proquest.com/docview/2478833603?pq-origsite=%requestingapplication%
PMID 33422083
PQID 2478833603
PQPubID 55248
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_b40a594772e64e66bd2df08231d5107b
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7794619
proquest_miscellaneous_2574345232
proquest_miscellaneous_2476853250
proquest_journals_2478833603
gale_infotracmisc_A650601633
gale_infotracacademiconefile_A650601633
gale_incontextgauss_ISR_A650601633
pubmed_primary_33422083
crossref_primary_10_1186_s12985_021_01489_0
crossref_citationtrail_10_1186_s12985_021_01489_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-09
PublicationDateYYYYMMDD 2021-01-09
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-09
  day: 09
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Virology journal
PublicationTitleAlternate Virol J
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References CM Dugdale (1489_CR9) 2020
E Avaniss-Aghajani (1489_CR25) 2020
CP West (1489_CR29) 2020; 95
DA Green (1489_CR22) 2020
K Pabbaraju (1489_CR17) 2020
DR Long (1489_CR1) 2020
Y Yang (1489_CR6) 2020
K Pabbaraju (1489_CR19) 2020; 9
PS Sullivan (1489_CR23) 2020; 6
NN Kinloch (1489_CR3) 2020; 222
ME Doll (1489_CR13) 2020
1489_CR12
A Afzal (1489_CR26) 2020
1489_CR11
X He (1489_CR8) 2020; 26
1489_CR16
1489_CR15
I Arevalo-Rodriguez (1489_CR2) 2020
JN Kanji (1489_CR18) 2020
LM Kucirka (1489_CR4) 2020; 173
JJ LeBlanc (1489_CR20) 2020; 128
AJ Jamal (1489_CR28) 2020
Y Pan (1489_CR7) 2020; 66
1489_CR5
1489_CR21
MG Thompson (1489_CR24) 2015; 9
T Ai (1489_CR14) 2020; 296
G Cao (1489_CR10) 2020
1489_CR27
References_xml – volume: 66
  start-page: 794
  issue: 6
  year: 2020
  ident: 1489_CR7
  publication-title: Clin Chem
  doi: 10.1093/clinchem/hvaa091
– year: 2020
  ident: 1489_CR13
  publication-title: Infect Control Hosp Epidemiol
  doi: 10.1017/ice.2020.224
– volume: 296
  start-page: E32
  issue: 2
  year: 2020
  ident: 1489_CR14
  publication-title: Radiology
  doi: 10.1148/radiol.2020200642
– year: 2020
  ident: 1489_CR17
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.01110-20
– ident: 1489_CR12
– ident: 1489_CR27
– year: 2020
  ident: 1489_CR6
  publication-title: MedRxiv
  doi: 10.1101/2020.02.11.20021493
– volume: 9
  start-page: 965
  year: 2020
  ident: 1489_CR19
  publication-title: J Assoc Med Microbiol Infect Dis Canada
  doi: 10.3138/jammi-2020-0026
– volume: 95
  start-page: 1127
  issue: 6
  year: 2020
  ident: 1489_CR29
  publication-title: Mayo Clin Proc
  doi: 10.1016/j.mayocp.2020.04.004
– year: 2020
  ident: 1489_CR2
  publication-title: medRxiv
  doi: 10.1101/2020.04.16.20066787
– volume: 26
  start-page: 672
  issue: 5
  year: 2020
  ident: 1489_CR8
  publication-title: Nat Med
  doi: 10.1038/s41591-020-0869-5
– volume: 128
  start-page: 104433
  year: 2020
  ident: 1489_CR20
  publication-title: J Clin Virol
  doi: 10.1016/j.jcv.2020.104433
– volume: 9
  start-page: 155
  issue: 3
  year: 2015
  ident: 1489_CR24
  publication-title: Influenza Other Respir Viruses
  doi: 10.1111/irv.12309
– volume: 173
  start-page: 262
  issue: 4
  year: 2020
  ident: 1489_CR4
  publication-title: Ann Intern Med
  doi: 10.7326/M20-1495
– year: 2020
  ident: 1489_CR9
  publication-title: Open Forum Infect Dis
  doi: 10.1093/ofid/ofaa559
– ident: 1489_CR16
– year: 2020
  ident: 1489_CR10
  publication-title: Jpn J Infect Dis
  doi: 10.7883/yoken.JJID.2020.165
– volume: 222
  start-page: 899
  issue: 6
  year: 2020
  ident: 1489_CR3
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiaa370
– year: 2020
  ident: 1489_CR25
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00753-20
– year: 2020
  ident: 1489_CR26
  publication-title: J Adv Res
  doi: 10.1016/j.jare.2020.08.002
– ident: 1489_CR11
– year: 2020
  ident: 1489_CR22
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00995-20
– year: 2020
  ident: 1489_CR28
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciaa848
– year: 2020
  ident: 1489_CR18
  publication-title: Off J Assoc Med Microbiol Infect Dis Canada
  doi: 10.3138/jammi-2020-0012
– ident: 1489_CR21
– ident: 1489_CR5
– ident: 1489_CR15
– volume: 6
  start-page: e19054
  issue: 2
  year: 2020
  ident: 1489_CR23
  publication-title: JMIR Public Health Surveill
  doi: 10.2196/19054
– year: 2020
  ident: 1489_CR1
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciaa722
SSID ssj0032679
Score 2.6038988
Snippet COVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR). Performance of many...
Background COVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR). Performance of...
BACKGROUND: COVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR). Performance of...
Abstract Background COVID-19 is diagnosed via detection of SARS-CoV-2 RNA using real time reverse-transcriptase polymerase chain reaction (rtRT-PCR)....
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 13
SubjectTerms Adult
Aged
Aged, 80 and over
Alberta
Canada
clinical examination
Coronaviruses
COVID-19
COVID-19 - diagnosis
COVID-19 - virology
COVID-19 infection
COVID-19 Nucleic Acid Testing - statistics & numerical data
Discordant testing
DNA-directed RNA polymerase
Evaluation
False negative rate
False Negative Reactions
False negative results
Female
Genes
Health aspects
Humans
Infections
Male
Medical laboratories
Middle Aged
Molecular Diagnostic Techniques - statistics & numerical data
nucleocapsid
Nucleocapsids
Pandemics
Patients
Polymerase chain reaction
Public health
Real-Time Polymerase Chain Reaction
reverse transcriptase polymerase chain reaction
Ribonucleic acid
RNA
SARS-CoV-2
SARS-CoV-2 - isolation & purification
Sensitivity and Specificity
Severe acute respiratory syndrome coronavirus 2
Short Report
Viral envelope proteins
Viral proteins
virology
viruses
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-yoHgRXb_qrhJF8CBl0yRNGm_r6LC74AerK3sLSZuMgnRkZ-bgf-97STtMEdaL1-altL-8vA_y8nuEvExnQzywMtRMlFJrXToWulJ22Ok4mrbLVb4f1cmFPLusL3dafWFNWKYHzsAdeclcbeAlPCgZlPId7yIeD1UdqJP2aH3B543JVLbBEJNoM16RadTRCrxagzeRMXWWWCQ0cUOJrf9vm7zjlKYFkzseaH6X3BlCR3qcP_keuRH6fXIzN5P8vU9ufRiOye-TszkoVaB9WCRab4p0EHQZ6ezTt9N3ZWXo59k5XSO_Rr94Qx3Fq7mQhALI41PqBrKSB-Ri_v7r7KQcmiaUrRJsXZrgmax8F4OUNVhVQLyBMMswFzjko4yFpnEmGCa0h9hBGhGFM1WoPDcxVl48JHv9sg-PCW1bxpyqXQSHJo0Enasa7UzkndcxNF1BqhFD2w6M4tjY4qdNmUWjbMbdAu424W5ZQV5v5_zKfBrXSr_FpdlKIhd2egAaYgcNsf_SkIK8wIW1yHbRYznNwm1WK3v65dweqzrx0QhRkFeDUFzCP7RuuJ0ASCBB1kTycCIJ27GdDo_6YwdzsLIcmxQIoRgMP98O40wscevDcpNkFMROEJJeI1NDwCdriIIL8iir5BYbISTnsNIF0RNlnYA3Hel_fE-E4hq7DFTmyf9A-4Dc5nmflcwckr311SY8hbht7Z-lLfoHYjw5QA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96oggiun5VT4ki-CDh0iZNG1_kXF3uDvzg9GTfQtomqyDtebv74H_vTJrWK8K-NlNoM9_JzG8IeRnuhjLHmcu5YLIoCma5a5hscNKx13XTV_l-Ukdn8mSZL-OB2zqWVQ42MRjqpqvxjPwgQ5x3IRQXb89_M5wahbercYTGVXINocuwpKtYjgkXRCYBaw-DbiazbDk0zZTqYA1-rsTeZEymJZYNTRxTwO__30pfclPTEspLPmlxh9yOwSQ97Ll_l1xx7Yxc78dL_pmRGx_jxfmM3OqP52jfdXSPnCxA7Bxt3SoAf1MEjKCdp_PP34_fs1TTL_NTukEEjnb1hlqKzbuQpgIbhqfURjiT--Rs8eHb_IjFsQqsVoJvmHYVl2nVeCdlDnYXeFJCIKa5dRlkrJy7srTaaS6KCqILqYUXVqcurTLtfVqJB2Sv7Vr3iNC65tyq3HpweVJLkMq0LKz2WVMV3pVNQtJhT00dMcdx9MUvE3KPUpmeDwb4YAIfDE_I6_Gd8x5xYyf1O2TVSIlo2eFBd7EyUflMJbnNNQhi5pR0SlVN1ni8YkwbMElFlZAXyGiDeBgtFtys7Ha9NsdfT82hygNijRAJeRWJfAf_UNvYvwA7gRBaE8r9CSUobD1dHuTJRIOxNv_EOyHPx2V8E4vgWtdtA42C6AqC1h00OQi7zCFOTsjDXkTHvREClAA4nZBiIryTzZuutD9_BMjxAucQpPrx7k9_Qm5mvUYxrvfJ3uZi655CzLapngXF_AtSUzhr
  priority: 102
  providerName: ProQuest
Title False negative rate of COVID-19 PCR testing: a discordant testing analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/33422083
https://www.proquest.com/docview/2478833603
https://www.proquest.com/docview/2476853250
https://www.proquest.com/docview/2574345232
https://pubmed.ncbi.nlm.nih.gov/PMC7794619
https://doaj.org/article/b40a594772e64e66bd2df08231d5107b
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ra9swED_6YKVfxta9vHVBG4N9GN5kS7aswRhp1tAG2pV0GfkmZFvKBsXZ8oD1v99JtkPNun4yWCeD7qG7s06_A3jjz4ZiQ0OTUBZyIUSoqSlDXrpOx1YWZV3le56eTPhomky3oG131DBweWtq5_pJTRZX7__8vv6MBv_JG3yWfliiz8rcPWOXGHNXArQNu-iZhDPUM745VcBIRcj24syt8_ZhjzEexzRjHT_l4fz_3bRveK1uReUNFzV8APeb2JL0a2V4CFumOoB7dbfJ6wPYO2vO0R_BaIirN6QyM4_7TRxeBJlbMvj6_fRLGElyMRiTlQPgqGYfiSbu7i5mqSiF9i3RDZrJY5gMj78NTsKmq0JYpIyuQmlyyqO8tIbzBLddFEmG65VUmxgTVkpNlmlpJGUix-CCS2aZlpGJ8lhaG-XsCexU88o8A1IUlOo00RY9HpcclTLKhJY2LnNhTVYGELU8VEUDOe46X1wpn3pkqapFoFAEyotA0QDebeb8qgE37qQ-cqLZUDqwbP9ivpipxvZUzqlOJOphbFJu0jQv49K6E8aoxB1J5AG8doJVDg6jcvU2M71eLtXp5Vj108QD1jAWwNuGyM5xDYVuri8gJxyCVofysEOJ9lp0h1v9Ua26q9h1MWAspTj8ajPsZroauMrM154mxeAKY9Y7aBKMCHmCYXIAT2uV3PCm1ewAREdZO8zrjlQ_f3jEceHaEETy-X-_-QL249qOQioPYWe1WJuXGK2t8h5si6nowW6_P7oc4fPo-Pxi3PP_PnrePP8Cpnw5ag
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ZbxMxEB6VVhwSQhCuhQIGgXhAq3pt72EkhNq0UdIjVGmL8mb28AYktClNItQ_xW9kZo_QFVLe-rqejZy5vZ75BuBteTckLHetz6WrwjB0Y24zV2U06TjXaVZV-Q6D_pnaH_vjNfjT9MJQWWXjE0tHnU1T-ka-JQjnXcqAy8_nv1yaGkW3q80IjUotDuzlbzyyzT4NdlG-74To7Z12-249VcBNA8nnrrYJV16S5VYpH90ObinCPETz2Ao8sHFuoyjWVnMZJhhclZa5jLVnvUToPPcSib97AzYUbgUdwcbO3vB41Ph-zIVKdD9K810lxLhp04mCrRlG1oi6oen4rqhQqRUKy4kB_8eFK4GxXbR5JQr27sO9On1l25W-PYA1W3TgZjXQ8rIDt47qq_oO3K0-CLKqz-kh7PdQ0S0r7KSEGmcEUcGmOet--TrYdT3NjrsjNifMj2LykcWM2oWRyyj45imLawCVR3B2LSx_DOvFtLBPgaUp53HgxzkGWaUV2oEXhbHORZaEuY0yB7yGpyatUc5p2MZPU552osBUcjAoB1PKwXAHPizfOa8wPlZS75ColpSEz10-mF5MTG3uJlE89jWqvrCBskGQZCLL6VLTy9AJhokDb0jQhhA4CirxmcSL2cwMTkZmO_BLjBwpHXhfE-VT_A9pXHdMICcItKtFudmiRBeRtpcbfTK1i5qZfwblwOvlMr1JZXeFnS5KmgDzOUyTV9D4qOzKx8zcgSeVii55IyUaAUragbClvC3mtVeKH99LkPOQJh94-tnqrb-C2_3To0NzOBgePIc7orIul-tNWJ9fLOwLzBjnycvaTBl8u27P8BeXh3Wg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=False+negative+rate+of+COVID-19+PCR+testing%3A+a+discordant+testing+analysis&rft.jtitle=Virology+journal&rft.au=Kanji%2C+Jamil+N&rft.au=Zelyas%2C+Nathan&rft.au=MacDonald%2C+Clayton&rft.au=Pabbaraju%2C+Kanti&rft.date=2021-01-09&rft.eissn=1743-422X&rft.volume=18&rft.issue=1&rft.spage=13&rft_id=info:doi/10.1186%2Fs12985-021-01489-0&rft_id=info%3Apmid%2F33422083&rft.externalDocID=33422083
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1743-422X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1743-422X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1743-422X&client=summon